RecruitingPhase 4NCT05968885

Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity

Evaluation of the Efficacy and Urodynamic Outcomes Between Intradetrusor onabotulinumtoxinA Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity


Sponsor

Mackay Memorial Hospital

Enrollment

300 participants

Start Date

Oct 1, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

To investigates the effects of botulinum toxin type A bladder injection compared to combined pharmacotherapy with Mirabegron and Solifenacin.


Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Combine Mirabegron and Solifenacin. and a procedure called Intradetrusor Botox® (onabotulinumtoxinA) injection for people with effect of drug, urinary bladder, overactive, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 20 Years to 90 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREIntradetrusor Botox® (onabotulinumtoxinA) injection

The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.

DRUGCombine Mirabegron and Solifenacin.

Combination pharmacotherapy


Locations(1)

Mackay Memorial Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05968885


Related Trials